EA200200151A1 - Сухая порошкообразная композиция - Google Patents

Сухая порошкообразная композиция

Info

Publication number
EA200200151A1
EA200200151A1 EA200200151A EA200200151A EA200200151A1 EA 200200151 A1 EA200200151 A1 EA 200200151A1 EA 200200151 A EA200200151 A EA 200200151A EA 200200151 A EA200200151 A EA 200200151A EA 200200151 A1 EA200200151 A1 EA 200200151A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dry powder
powder composition
carbohydrate
agent
hydrophobic
Prior art date
Application number
EA200200151A
Other languages
English (en)
Inventor
Питер Джексон
Original Assignee
КВАДРАНТ ХЕЛТКЭА (Ю Кей) ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by КВАДРАНТ ХЕЛТКЭА (Ю Кей) ЛИМИТЕД filed Critical КВАДРАНТ ХЕЛТКЭА (Ю Кей) ЛИМИТЕД
Publication of EA200200151A1 publication Critical patent/EA200200151A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Гидрофильный терапевтический агент получают в устойчивой при хранении форме, подходящей для введения пациенту. Агент состоит из гидрофобно дериватизированного углевода с использованием образования ионных пар для получения раствора агента и углевода.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200151A 1999-07-12 2000-07-11 Сухая порошкообразная композиция EA200200151A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9916316.4A GB9916316D0 (en) 1999-07-12 1999-07-12 Dry powder compositions
PCT/GB2000/002661 WO2001003673A1 (en) 1999-07-12 2000-07-11 Dry powder compositions

Publications (1)

Publication Number Publication Date
EA200200151A1 true EA200200151A1 (ru) 2002-06-27

Family

ID=10857101

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200151A EA200200151A1 (ru) 1999-07-12 2000-07-11 Сухая порошкообразная композиция

Country Status (12)

Country Link
US (1) US6551622B1 (ru)
EP (1) EP1194126A1 (ru)
JP (1) JP2003504325A (ru)
CN (1) CN1360496A (ru)
AU (1) AU766042B2 (ru)
BR (1) BR0012444A (ru)
CA (1) CA2375640A1 (ru)
EA (1) EA200200151A1 (ru)
GB (1) GB9916316D0 (ru)
IL (1) IL147390A0 (ru)
MX (1) MXPA02000500A (ru)
WO (1) WO2001003673A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503231B1 (en) * 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
WO2002064193A2 (en) * 2000-12-14 2002-08-22 Georgia Tech Research Corporation Microneedle devices and production thereof
KR20050044523A (ko) * 2001-11-19 2005-05-12 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
GB0208608D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
BRPI0412029A (pt) * 2003-06-30 2006-09-05 Alza Corp formulações para microprojeções revestidas contendo contra-ìons não-voláteis
JP2007503268A (ja) * 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
US20070172517A1 (en) * 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
GB0416861D0 (en) * 2004-07-29 2004-09-01 Quadrant Drug Delivery Ltd Composition
WO2006076222A2 (en) * 2005-01-10 2006-07-20 Glaxo Group Limited Pharmaceutical formulations
WO2007061781A1 (en) * 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
US20080319404A1 (en) * 2005-12-21 2008-12-25 Pekurovsky Mikhail L Microneedle Devices
US20120064126A1 (en) * 2009-03-26 2012-03-15 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
TWM410270U (en) * 2011-04-13 2011-08-21 Darfon Electronics Corp Foldable keyboard assembly and portable electronic module

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5260273A (en) * 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5994314A (en) * 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
ATE416755T1 (de) * 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
GB2288732B (en) 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
EP0773781B1 (en) 1994-08-04 2003-10-22 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
WO1996027393A1 (en) * 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
US5958455A (en) 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US6093816A (en) * 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
EP0994887B1 (en) 1997-07-03 2002-11-27 Elan Drug Delivery Limited Modified glycosides, compositions comprised thereof and methods of use thereof
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof

Also Published As

Publication number Publication date
CA2375640A1 (en) 2001-01-18
US6551622B1 (en) 2003-04-22
BR0012444A (pt) 2002-04-02
EP1194126A1 (en) 2002-04-10
JP2003504325A (ja) 2003-02-04
CN1360496A (zh) 2002-07-24
WO2001003673A1 (en) 2001-01-18
AU766042B2 (en) 2003-10-09
IL147390A0 (en) 2002-08-14
GB9916316D0 (en) 1999-09-15
MXPA02000500A (es) 2005-08-16
AU6166600A (en) 2001-01-30

Similar Documents

Publication Publication Date Title
EA200200151A1 (ru) Сухая порошкообразная композиция
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
ES2152412T3 (es) Preparacion farmaceuticamente estable de oxaliplatino.
SE8702907D0 (sv) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
BR9702362A (pt) Novas fomrulações lìquidas estáveis à base de paracetamol e seu modo de preparação.
HN1999000159A (es) Administracion de agente activo en polvo seco.
ES2150438T3 (es) Composicion de esferonizacion a base de celulosa microcristalina.
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
BR0109346A (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
EA200101206A1 (ru) Применение биоразлагаемых микросфер, высвобождающих противораковый агент, для лечения глиобластомы
ES2179832T3 (es) Formas de administracion orales con contenido en flupirtina solida, con liberacion controlada del principio activo.
BR0109515A (pt) Derivados da apomorfina e métodos para seu uso
FI940696A (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
EA199900376A1 (ru) Местный анестетик для наружного применения
EA200201044A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин
ES2033021T3 (es) Agente con efecto destructivo a tumores malignos, procedimiento para su obtencion y preparacion para la aplicacion en la terapia de enfermos de cancer.
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
IL152328A (en) Preparations containing a combination of defibrotide and one or more hematopoietic factors and their use
PE22995A1 (es) Composicion de tiotepa liofilizada estable
LV11818A (lv) Jauna farmaceitiska kompozicija stabilas pulverveida zalu formas pagatavosanai
EA200100214A1 (ru) Применение производных камптотецина с пониженной гастроинтестинальной токсичностью
DK0450123T3 (da) Farmaceutisk præparat til topisk administration indeholdende dichlofenac-natrium
TR200000890T2 (tr) Topik ilacın üretilmesi için -amino levülozik asidin kullanılması
DE60135845D1 (de) Pralmorelin-haltige nasentropfen-präparate